This list is an analysis based on recent market events. It's not an investment recommendation.
About
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Parnell Pharmaceuticals stocks are traded under the ticker 58P.MU.
In which sector is Parnell Pharmaceuticals located?▼
Parnell Pharmaceuticals operates in the Health & Wellness sector.
When did Parnell Pharmaceuticals complete a stock split?▼
Parnell Pharmaceuticals has not had any recent stock splits.
Where is Parnell Pharmaceuticals headquartered?▼
Parnell Pharmaceuticals is headquartered in Alexandria, Australia.